Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Former Chief Financial Officer | March 01, 2019 | March 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date March 01, 2019 · Filed March 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2029-02-28 | Direct | 60,000 |
Reported balance
After 2019-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-01 · Grant · Acquired 60,000 · Balance 60,000 F1: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 6, 2020 19:09 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001209191-20-016873 · doc4.xml · derivative · entry 1 Ward Michael James · CIK 0001569975 · Former Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: The shares subject to the option shall vest monthly over 48 months beginning on the one-month anniversary of March 1, 2019 (the "Grant Date") such that the option shall be fully vested and exercisable on the four-year anniversary of the Grant Date. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:31 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 59,590 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001209191-18-053817 · doc4.xml · derivative · entry 1 Ward Michael James · CIK 0001569975 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,590 Underlying: Common Stock · 59,590 shares Expires 2028-09-30 F1 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on October 1, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.